❗ #ERSALERTS Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in children with cystic fibrosis aged 2–5 years (TIMBERLINE Trial VX21-121-105): a phase 3, open-label study
Presented today by Prof Marcus Mall at #ERS2026
@lancetrespirmed.bsky.social
